Table 4

Dosing for DOACs on discharge from the emergency department

DOAC regimen*Edmonton academic sites n=34Edmonton community-based sites
n=56
Rural Alberta
n=16
Regina n=10Total n=116
Rivaroxabann=31 (91.2%)n=56 (100%)n=15 (93.8%)n=9 (90.0%)111 (95.7%)
 15 mg two times per day, 20QD†13 (41.9%)38 (67.9%)10 (66.7%)8 (88.9%)69 (62.2%)
 15 mg two times per day†12 (35.3%)7 (12.5%)2 (13.3%)‡1 (11.1%)22 (19.8%)
 15 mg two times per day, 15QD01 (1.8%)001 (0.9%)
 15 mg QD1 (3.2%)0001 (0.9%)
 20 mg QD1 (3.2%)0001 (0.9%)
 Other01 (1.8%)1 (6.7%)n=02 (1.8%)
 Not documented4 (12.9%)9 (16.1%)2 (13.3%)015 (13.5%)
Apixabann=3n=0n=1n=15 (4.3%)
 10 mg two times per day x 7 days then 5 mg two times per day*20103
 5 mg two times per day10012
Dosing as per PM27 (79.4%)45 (80.4%)11 (68.8%)9 (90%)92 (79.3%)
 Dosing outside PM3 (8.8%)2 (3.6%)3 (18.8%)1 (10%)9 (7.8%)
 Not documented4 (11.8%)9 (16.1%)2 (12.5%)015 (12.9%)
  • *Dosing as per product monographs: rivaroxaban 15 mg two times per dayx21 days then rivaroxaban 20 mg daily; apixaban 10 mg two times per dayx7 days then apixaban 5 mg two times per day; parenteral anticoagulant x 5–10 days followed by dabigatran 150 mg two times per day.3–5

  • †Classified as dosing consistent with Health Canada-approved product monograph.

  • ‡Both had creatinine clearance <30 mL/min; hence were classified as discordant with Health Canada-approved product monograph.

  • DOAC, direct oral anticoagulant; PM, product monograph.